Efficacy

Beleodaq (Belinostat) for the Treatment of Lymphoma

Beleodaq (belinostat) is an anticancer medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This is a diverse group of aggressive lymphomas that affect the T-cells of the immune system. The efficacy of Beleodaq in this indication was demonstrated in a multicenter, single-arm clinical trial. In this study, belinostat was administered intravenously and showed a 25.8% overall response rate with a median duration of response of 8.4 months. While these results are promising, it is important to note that PTCL is a rare and difficult-to-treat type of lymphoma, and responses to treatment can vary significantly among patients.

Beleodaq works as a histone deacetylase inhibitor, which leads to the accumulation of acetylated histones and other proteins, resulting in cell cycle arrest and/or apoptosis of cancer cells. Despite its approval for PTCL, the effectiveness of Beleodaq for other types of lymphoma is not well established and is typically not used outside of its approved indication without further evidence from clinical trials or studies.

Brukinsa (Zanubrutinib) for the Treatment of Lymphoma

Brukinsa (zanubrutinib) is another medication approved by the FDA for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy. Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that helps to block the growth and spread of cancer cells. The approval of Brukinsa was based on overall response rates observed in clinical trials. In a phase 2 trial, zanubrutinib demonstrated an overall response rate of 84% with a 59% complete response rate in patients with relapsed or refractory MCL. The median duration of response has not been reached, indicating the potential for long-term benefits.

Moreover, Brukinsa is being investigated for its efficacy in other B-cell malignancies, including different types of lymphoma such as Waldenström's macroglobulinemia. Clinical trials are ongoing to determine the full potential and efficacy of zanubrutinib in these additional indications. As with any medication, the efficacy of Brukinsa can vary based on individual patient factors and disease characteristics, and it is generally used in accordance with its approved indications unless new evidence supports its use in other forms of lymphoma.